流感疫苗的官方批签发控制:是否仍然有用?
该研究梳理2006至2016年OCABR网络内流感疫苗通报并归为32例,评估其对企业和欧洲控制实验室沟通的影响。结果显示OMCL网络约检测5850批,32例通报多涉及生产问题,多数由生产商在市场投放前自行撤回,但3例由欧洲控制实验室检出质量不合格并导致13批撤回。作者认为官方批签发仍合理。
要点
- 2006至2016年OMCL网络约检测5850批流感疫苗,通报归为32例。
- 多数通报涉及生产问题,且多由生产商在市场投放前自行撤回批次。
- 3例由欧洲控制实验室检出质量不合格,导致13批撤回,生产商未识别。
核心结论
- 2006至2016年OMCL网络检出13批不符合流感疫苗规格的批次,这些批次生产商未能识别,作者认为官方批签发仍合理。
研究设计与样本
- 研究将2006至2016年OCABR网络内 circulated 的流感疫苗通报汇编并归为32例,评估其影响并检查企业与相应欧洲控制实验室间的沟通路径。
主要发现
- 2006至2016年OMCL网络约检测5850批,其中观察到属于32例的通报。
- circulated 通报的 predominant 比例涉及生产问题。
- 多数情况下生产商在市场投放前自行撤回批次,但3例由相应欧洲控制实验室检出质量不合格导致13批撤回。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The governmental quality control of human vaccines is a long established tradition in many European countries. In Germany, vaccines have been controlled by a governmental agency since 1935. In the beginning, vaccine production and control was a purely national activity. However, that changed fundamentally in 1994 when the so-called Official Control Authority Batch Release Network (OCABR) was implemented shortly after the establishment of the European Union. Today, Official Medicinal Control Laboratories (OMCLs) are part of the European OCABR Network. In many European countries, OMCLs experimentally test every batch of human vaccines before they enter the market. We wanted to gain insights into the benefits of batch release by the Network and address the question whether batch release is still useful. This question was investigated in the context of influenza vaccines. METHODS: Notifications on influenza vaccines circulated from 2006 to 2016 within the OCABR network were compiled and organized into 32 cases. The impact of these findings was evaluated, and the communication pathways between companies and respective European control laboratories were examined. RESULTS: Approximately 5850 batches were tested by the OMCL network between 2006 and 2016. Among these, notifications belonging to 32 cases were observed. The predominant proportion of the circulated notifications related to manufacturing issues. In most cases, the manufacturer itself had withdrawn the batches before they entered the market. However, in three cases, batches of insufficient quality were detected by the respective European Control Laboratory leading to withdrawal of 13 batches. CONCLUSION: 13 batches which did not meet the specifications of influenza vaccine were detected by the OMCL network between 2006 and 2016 which would not have been identified by the manufacturer. This demonstrates the impact of governmental batch release. Together with the intrinsic values of the OCABR system and keeping in mind that vaccines are given to healthy often young individuals, governmental batch release of influenza vaccines is still justified.
引用
- Kretzschmar E, Muckenfuss H, Pfleiderer M, et al. Official batch control of influenza vaccines: Is it still useful? Vaccine. 2018. PMID: 29580639. doi:10.1016/j.vaccine.2018.02.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。